NCT02427607View on ClinicalTrials.gov

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 12, 2015

Primary Completion Date

September 21, 2016

Study Completion Date

November 9, 2016

Conditions
Epilepsy
Interventions
DRUG

Perampanel

Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.

Trial Locations (8)

Unknown

Matsuyama

Sapporo

Inashiki-gun

Uji

Sakai

Matsue

Nerima-Ku

Niigata

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02427607 - An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects | Biotech Hunter | Biotech Hunter